Long Non-coding RNA MALAT1 Regulates Cell Proliferation and Apoptosis Via MiR-135b-5p/GPNMB Axis in Parkinson's Disease Cell Model

Overview

Journal Biol Res

Specialty Biology

Date 2021 Mar 17

PMID 33726823

Citations 18

Authors

Kefeng Lv

Yuhua Liu

Yanbing Zheng

Shaowen Dai

Peifeng Yin

Haifeng Miao

Affiliations

Soon will be listed here.

Abstract

Backgrounds: Parkinson's disease (PD) is a common age-related neurodegenerative disorder worldwide. This research aimed to investigate the effects and mechanism underlying long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in PD.

Methods: SK-N-SH and SK-N-BE cells were treated with MPP to establish the MPP-stimulated cell model of PD, and MALAT1 expression was determined. Then, the effects of MALAT1 depletion on cell proliferation and apoptosis were determined in the MPP-stimulated cell model of PD. Besides, the correlations between microRNA-135b-5p (miR-135b-5p) and MALAT1 or glycoprotein nonmetastatic melanoma protein B (GPNMB) in MPP-stimulated cell model of PD were explored.

Results: MALAT1 was increasingly expressed and downregulation of MALAT1 promoted cell proliferation while inhibited apoptosis in MPP-stimulated cells. Besides, miR-135b-5p was a target of MALAT1 and directly targeted to GPNMB. Further investigation indicated that suppression of MALAT1 regulated cell proliferation and apoptosis by miR-135b-5p/GPNMB axis.

Conclusion: Our findings reveal that MALAT1/miR-135b-5p/GPNMB axis regulated cell proliferation and apoptosis in MPP-stimulated cell model of PD, providing a potential biomarker and therapeutic target for PD.

Citing Articles

MiRNAs as major players in brain health and disease: current knowledge and future perspectives.

Kapplingattu S, Bhattacharya S, Adlakha Y Cell Death Discov. 2025; 11(1):7.

PMID: 39805813 PMC: 11729916. DOI: 10.1038/s41420-024-02283-x.

Potential Regulation of the Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript1 by Estrogen in Parkinson's Disease.

Adel E, Nicolas M Life (Basel). 2025; 14(12.

PMID: 39768369 PMC: 11727754. DOI: 10.3390/life14121662.

miR-135b: An emerging player in cardio-cerebrovascular diseases.

Shao Y, Xu J, Chen W, Hao M, Liu X, Zhang R J Pharm Anal. 2024; 14(10):100997.

PMID: 39211791 PMC: 11350494. DOI: 10.1016/j.jpha.2024.100997.

Parkinson's Disease and MicroRNAs: A Duel Between Inhibition and Stimulation of Apoptosis in Neuronal Cells.

Saadh M, Faisal A, Adil M, Zabibah R, Mamadaliev A, Jawad M Mol Neurobiol. 2024; 61(11):8552-8574.

PMID: 38520611 DOI: 10.1007/s12035-024-04111-w.

Possible role of lncRNAs in amelioration of Parkinson's disease symptoms by transplantation of dopaminergic cells.

Amini A, Esmaeili F, Golpich M NPJ Parkinsons Dis. 2024; 10(1):56.

PMID: 38472261 PMC: 10933336. DOI: 10.1038/s41531-024-00661-x.

References

Kabra A, Sharma R, Kabra R, Baghel U . Emerging and Alternative Therapies For Parkinson Disease: An Updated Review. Curr Pharm Des. 2018; 24(22):2573-2582. DOI: 10.2174/1381612824666180820150150. View

Lan Y, Zhou J, Liu J, Huo X, Wang Y, Liang J . Uncaria rhynchophylla Ameliorates Parkinson's Disease by Inhibiting HSP90 Expression: Insights from Quantitative Proteomics. Cell Physiol Biochem. 2018; 47(4):1453-1464. DOI: 10.1159/000490837. View

Zeng R, Luo D, Li H, Zhang Q, Lei S, Chen J . MicroRNA-135b alleviates MPP-mediated Parkinson's disease in in vitro model through suppressing FoxO1-induced NLRP3 inflammasome and pyroptosis. J Clin Neurosci. 2019; 65:125-133. DOI: 10.1016/j.jocn.2019.04.004. View

Hare D, Adlard P, Doble P, Finkelstein D . Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Metallomics. 2013; 5(2):91-109. DOI: 10.1039/c2mt20164j. View

Shioya M, Obayashi S, Tabunoki H, Arima K, Saito Y, Ishida T . Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol Appl Neurobiol. 2010; 36(4):320-30. DOI: 10.1111/j.1365-2990.2010.01076.x. View

Liu W, Zhang Q, Zhang J, Pan W, Zhao J, Xu Y . Long non-coding RNA MALAT1 contributes to cell apoptosis by sponging miR-124 in Parkinson disease. Cell Biosci. 2017; 7:19. PMC: 5401610. DOI: 10.1186/s13578-017-0147-5. View

Sveinbjornsdottir S . The clinical symptoms of Parkinson's disease. J Neurochem. 2016; 139 Suppl 1:318-324. DOI: 10.1111/jnc.13691. View

Moloney E, Moskites A, Ferrari E, Isacson O, Hallett P . The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress. Neurobiol Dis. 2018; 120:1-11. PMC: 6748034. DOI: 10.1016/j.nbd.2018.08.013. View

Andican G, Konukoglu D, Bozluolcay M, Bayulkem K, Firtiina S, Burcak G . Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson's disease. Acta Neurol Belg. 2012; 112(2):155-9. DOI: 10.1007/s13760-012-0015-3. View

10.

Szulzewsky F, Pelz A, Feng X, Synowitz M, Markovic D, Langmann T . Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS One. 2015; 10(2):e0116644. PMC: 4320099. DOI: 10.1371/journal.pone.0116644. View

11.

Nelson P, Wang W, Rajeev B . MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol. 2008; 18(1):130-8. PMC: 2859437. DOI: 10.1111/j.1750-3639.2007.00120.x. View

12.

Kraus T, Haider M, Spanner J, Steinmaurer M, Dietinger V, Kretzschmar H . Altered Long Noncoding RNA Expression Precedes the Course of Parkinson's Disease-a Preliminary Report. Mol Neurobiol. 2016; 54(4):2869-2877. DOI: 10.1007/s12035-016-9854-x. View

13.

Bernard D, Prasanth K, Tripathi V, Colasse S, Nakamura T, Xuan Z . A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. EMBO J. 2010; 29(18):3082-93. PMC: 2944070. DOI: 10.1038/emboj.2010.199. View

14.

Murthy M, Blauwendraat C, Guelfi S, Hardy J, Lewis P, Trabzuni D . Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson's disease on chromosome 7p15.3. Neurogenetics. 2017; 18(3):121-133. PMC: 5522530. DOI: 10.1007/s10048-017-0514-8. View

15.

Lu M, Huang Y, Sun W, Li P, Li L, Li L . miR-135b-5p promotes gastric cancer progression by targeting CMTM3. Int J Oncol. 2018; 52(2):589-598. DOI: 10.3892/ijo.2017.4222. View

16.

Ren R, Wu J, Zhou M . MiR-135b-5p affected malignant behaviors of ovarian cancer cells by targeting KDM5B. Eur Rev Med Pharmacol Sci. 2020; 24(7):3548-3554. DOI: 10.26355/eurrev_202004_20815. View

17.

Wu P, Zuo X, Deng H, Liu X, Liu L, Ji A . Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases. Brain Res Bull. 2013; 97:69-80. DOI: 10.1016/j.brainresbull.2013.06.001. View

18.

Cai L, Tu L, Huang X, Huang J, Qiu N, Xie G . LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson's disease. Mol Brain. 2020; 13(1):130. PMC: 7513532. DOI: 10.1186/s13041-020-00656-8. View

19.

Hebert S, De Strooper B . Molecular biology. miRNAs in neurodegeneration. Science. 2007; 317(5842):1179-80. DOI: 10.1126/science.1148530. View

20.

Hebert S, De Strooper B . Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 2009; 32(4):199-206. DOI: 10.1016/j.tins.2008.12.003. View